Scientists have identified a protein that sabotages one of modern medicine's most promising cancer treatments, and disabling it could transform how doctors fight tumors that currently resist therapy.
Researchers at Columbia University and University Hospital Tübingen discovered that a protein called NFIL3 gradually weakens CAR T cells, engineered immune soldiers designed to hunt down and kill cancer. When they knocked out NFIL3 using gene-editing tools, the treated cells stayed potent longer, multiplied faster, and destroyed tumors more effectively in animal tests.
The findings, published in Cancer Discovery, point toward a straightforward intervention: switch off the protein that's sabotaging the therapy.
CAR T-cell therapy represents the cutting edge of personalized cancer treatment. Doctors extract a patient's own immune cells, reprogram them to recognize cancer cells, and inject them back to seek and destroy tumors. The approach has delivered stunning results against blood cancers like leukemia and lymphoma. But against solid tumors, the therapy has largely flopped. That gap prompted researchers led by Columbia's Prof. Michel Sadelain, a pioneer in CAR T development, to dig deeper into what goes wrong.
The team screened roughly 400 transcription factors, the proteins that act like on-off switches for genes inside cells. NFIL3 emerged as a major culprit. The protein triggers exhaustion, a process where CAR T cells gradually lose their fighting capacity.
Using CRISPR gene-editing technology to slice out the gene producing NFIL3, researchers found the edited cells performed dramatically better. They sustained activity longer, reproduced more vigorously, and maintained stronger tumor-killing power across multiple mouse models.
The discovery opens a direct path to improving CAR T therapy for solid tumors, cancers that have proven stubbornly resistant to the treatment. Prof. Judith Feucht of University Hospital Tübingen, who co-led the research, emphasizes the clinical potential. She splits her time between laboratory research and treating pediatric cancer patients, keeping one eye always on how discoveries translate to bedside care.
The strategy remains in early stages. Human trials are years away, and additional research must confirm that removing NFIL3 is safe and effective in patients. But the mouse data suggests a powerful intervention hiding in plain sight, one that could unlock CAR T therapy for cancer types that currently have few good options.
Author Jessica Williams: "If NFIL3 really is the bottleneck researchers think it is, blocking it could finally crack the solid tumor problem that's limited CAR T's reach so far."
Comments